Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov 17:14:1329811.
doi: 10.3389/fphar.2023.1329811. eCollection 2023.

Editorial: Evolution in respiratory pharmacology

Barbara Ruaro  1 , Riccardo Pozzan  1   2 , Alessia Giovanna Andrisano  1   3 , Marco Confalonieri  1 , Nilesh Sudhakar Ambhore  3
Affiliations
Editorial

Editorial: Evolution in respiratory pharmacology

Barbara Ruaro et al. Front Pharmacol. .
No abstract available

Keywords: airway dysfunction; airway inflammation; lung diseases; respiratory medicine; respiratory pharmacology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Evolution in respiratory pharmacology

References

    1. Baratella E., Ruaro B., Giudici F., Wade B., Santagiuliana M., Salton F., et al. (2021). Evaluation of correlations between genetic variants and high-resolution computed tomography patterns in idiopathic pulmonary fibrosis. Diagn. (Basel) 11 (5), 762. 10.3390/diagnostics11050762 - DOI - PMC - PubMed
    1. Calzetta L., Matera M. G., Coppola A., Rogliani P. (2021). Prospects for severe asthma treatment. Curr. Opin. Pharmacol. 56, 52–60. 10.1016/j.coph.2020.10.021 - DOI - PubMed
    1. Cazzola M., Matera M. G., Calzetta L., Rogliani P. (2021). Editorial overview: respiratory: Pulmonary pharmacology-The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives. Curr. Opin. Pharmacol. 60, 54–58. 10.1016/j.coph.2021.07.001 - DOI - PMC - PubMed
    1. Confalonieri P., Volpe M. C., Jacob J., Maiocchi S., Salton F., Ruaro B., et al. (2022). Regeneration or repair? The role of alveolar epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Cells 11 (13), 2095. 10.3390/cells11132095 - DOI - PMC - PubMed
    1. Matera M. G., Cazzola M., Page C. (2021). Prospects for COPD treatment. Curr. Opin. Pharmacol. 56, 74–84. 10.1016/j.coph.2020.11.003 - DOI - PubMed

Publication types

LinkOut - more resources